Compare Intuitive Surgical, Inc. (ISRG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuitive Surgical, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Intuitive Surgical, Inc. trades at $351.3 (market cap $125.08B), while Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B). The key difference: Intuitive Surgical, Inc. is far larger — about 81.8× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| ISRG | RXRX | |
|---|---|---|
Market Cap | $125.08B | $1.53B |
Sector | Health | Health |
52-Week High | $592.85 | $6.79 |
52-Week Low | $345.42 | $2.84 |
Enterprise Value | $116.45B | $946.50M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $350.06, down 1.34% on the day and near its 52-week low of $344.55. The stock is in a bearish technical trend despite strong fundamentals: Q2 2026 EPS beat estimates at $2.80 vs. $2.48 expected, revenue grew to $10.06B in 2025, and net income margin expanded to 28.45%. However, slowing U.S. procedure growth and a cautious 2026 outlook have pressured shares, with recent news highlighting a nearly 40% decline year-to-date.
The outlook remains mixed: robust profitability and a 69.6% analyst buy rating with a $504.56 consensus target suggest long-term value, but near-term risks include valuation concerns (P/E 40.5), competitive pressures, and macroeconomic headwinds. Investors face a divergence between solid execution and market sentiment driven by growth deceleration fears.
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
